Mobic Tablets Recalled for Incorrect Package Insert Labeling
Boehringer Ingelheim is recalling 128 bottles of Mobic 15 mg tablets because they were packaged with an incorrect insert.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences. The issue is a packaging/labeling defect.
Plain-English summary
Boehringer Ingelheim Pharmaceuticals, Inc. is recalling 128 bottles of Mobic (meloxicam) tablets, 15 mg, 100-count bottles. The recall is due to a labeling issue where the product was packaged with an incorrect or missing package insert.
The affected product is identified by Lot 754037 and NDC 0597-0030-01. The tablets were distributed in Colorado and Ohio. This is a Class III recall, indicating that the labeling error is unlikely to cause adverse health consequences.
Consumers who have this specific lot of Mobic tablets should contact their healthcare provider or pharmacist for guidance. The source text does not specify a particular action such as returning the product to a pharmacy, but standard practice for prescription medication recalls involves consulting a medical professional.
The recalled product
- Product
- Mobic (meloxicam) tablets, 15 mg, package in 100-count bottle, Rx only, Dist. by: Boehringer Ingelheim (BI) Pharmaceuticals, Inc., Ridgefield, CT 06877 USA, Lic. from: BI Int'l GmbH, Made in Italy, NDC 0597-0030-01
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 128
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot 754037
Distribution
Related recalls
Same manufacturer · Boehringer Ingelheim Pharmaceuticals, Inc.
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- HighPrescription Drug Recall: Jardiance Empagliflozin 25 mg Label Mix-Up
FDA (Drugs) · 2023-03-29
- ModerateMicardis (Telmisartan) 80 mg Tablets Recall Due to Subpotency
FDA (Drugs) · 2021-06-09
- ModerateBoehringer Ingelheim Recalls Catapres Tablets Due to Dissolution Testing Anomaly
FDA (Drugs) · 2020-11-04
- ModerateBoehringer Ingelheim Recalls Catapres Tablets Due to Dissolution Testing Anomaly
FDA (Drugs) · 2020-11-04
Same hazard · mis labeling
See all →- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- HighByron White A-L Complex Herbal Supplement Recalled for Undeclared Walnut
FDA (Food) · 2026-09-02
- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02